CAR T-Cell Immunotherapy in Minority Patients with Lymphoma
Guido Ghilardi(Hospital of the University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Wei‐Ting Hwang(California University of Pennsylvania), Connor B. Grady(University of Pennsylvania), Rebecca Yelton(University of Pennsylvania), Carmen E. Guerra(Novartis (Switzerland)), Levanto Schachter(Oregon Health & Science University), Elise A. Chong(Hospital of the University of Pennsylvania), Abigail Doucette(University of Pennsylvania), Linhui Chen(Hospital of the University of Pennsylvania), Stefan K. Barta(University of Pennsylvania), Giulia Gabrielli(University of Turin), Eneida R. Nemecek(Oregon Health & Science University), Hatcher J. Ballard(University of Pennsylvania), Alfred L. Garfall(University of Pennsylvania), Daniel J. Landsburg(University of Pennsylvania), Andy I. Chen(Scripps Research Institute), Luca Paruzzo(Hospital of the University of Pennsylvania), David L. Porter(Chapman University), Staci Williamson(Oregon Health & Science University), Stephen J. Schuster(Hospital of the University of Pennsylvania), Richard T. Maziarz(Oregon Health & Science University), Raymone Pajarillo(Hospital of the University of Pennsylvania), Sunita D. Nasta(University of Pennsylvania), Elizabeth Weber(Hospital of the University of Pennsylvania), Cara Curley(Hospital of the University of Pennsylvania), Jakub Svoboda(UPMC Hillman Cancer Center), Griffin White(Hospital of the University of Pennsylvania), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania)
Cited by 20
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523